It is made available under a CC-BY-NC-ND 4.0 International license .

1	Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25
2	in humans but not mice
3	Authors: Sara A. Healy ¹ , Charles Anderson ¹ , Bruce J. Swihart ² , Agnes Mwakingwe ¹ , Erin E.
4	Gabriel ^{2,3} , Hope Decederfelt ⁴ , Charlotte V. Hobbs ¹ , Kelly M. Rausch ¹ , Daming Zhu ¹ , Olga
5	Muratova ¹ , Raul Herrera ¹ , Puthupparampil V. Scaria ¹ , Nicholas J. MacDonald ¹ , Lynn E.
6	Lambert ¹ , Irfan Zaidi ¹ , Camila H. Coelho ¹ , Jonathan P. Renn ¹ , Yimin Wu ^{1&} , David L. Narum ¹ ,
7	Patrick E. Duffy ^{1*}
8	Affiliations: ¹ Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy
9	and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
10	² Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National
11	Institutes of Health, Bethesda, Maryland, USA.
12	³ Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm,
13	Sweden.
14	⁴ Pharmacy Department. Clinical Center. National Institutes of Health, Bethesda, Maryland,
15	USA.
16	*Correspondence to: Patrick E. Duffy, Laboratory of Malaria Immunology and Vaccinology,
17	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
18	MD 20892-8180, USA. patrick.duffy@nih.gov
19	&Current affiliation: PATH-Malaria Vaccine Initiative
20	Conflict of interest statement: The authors have declared that no conflict of interest exists.
21	

It is made available under a CC-BY-NC-ND 4.0 International license .

22 Abstract

23	Background. Vaccines that block human-to-mosquito <i>Plasmodium</i> transmission are needed for
24	malaria eradication and clinical trials have targeted zygote antigen Pfs25 for decades. We
25	reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced
26	significant serum functional activity in both US and Malian adults. However, antibody titers
27	declined rapidly, and transmission-reducing activity required four vaccine doses. Functional
28	immunogenicity and durability must be improved before advancing TBV further in clinical
29	development. We hypothesized that the pre-fertilization protein Pfs230 alone or in combination
30	with Pfs25 would improve functional activity.
31	Methods. Transmission-blocking vaccine candidates based on gamete antigen Pfs230 or Pfs25
32	were conjugated with Exoprotein A, formulated in Alhydrogel®, and administered to mice, rhesus
33	macaques, and humans. Antibody titers were measured by ELISA and transmission-reducing
34	activity was assess by the Standard Membrane Feeding Assay.
35	Results. Pfs25-EPA/Alhydrogel [®] and Pfs230D1-EPA/Alhydrogel [®] induced similar serum
36	functional activity in mice, but Pfs230D1-EPA induced significantly greater activity in rhesus
37	monkeys that was enhanced by complement. In U.S. adults, two vaccine doses induced
38	complement-dependent activity in 4 of 5 Pfs230D1-EPA/Alhydrogel® recipients but no
39	significant activity in five Pfs25-EPA recipients, and combination with Pfs25-EPA did not
40	increase activity over Pfs230D1-EPA alone.
41	Conclusion. The complement-dependent functional immunogenicity of Pfs230D1-EPA
42	represents a significant improvement over Pfs25-EPA. The rhesus model is more predictive of
43	the functional human immune response to Pfs230D1 than is the mouse model.
44	Trial Registration. ClinicalTrials.gov NCT02334462

It is made available under a CC-BY-NC-ND 4.0 International license .

- 45 **Funding.** This work was supported by the Intramural Research Program of the National Institute
- 46 of Allergy and Infectious Diseases, National Institutes of Health.

47

- -10
- 49

It is made available under a CC-BY-NC-ND 4.0 International license .

50 Introduction

51	The world has achieved significant strides in malaria control with roughly half of countries
52	having eliminated the disease, but existing tools failed to achieve elimination despite
53	comprehensive application in African settings $(1, 2)$, and recent progress to reduce malaria cases
54	has stalled globally and been reversed in some areas (3). Vaccines have been essential for
55	elimination of infectious agents like smallpox, polio, and measles by halting their onward
56	transmission, conferring major benefits to human health and economies (4-6). Malaria
57	transmission-blocking vaccines (TBV) were conceived in the 1970's as a tool to interrupt
58	parasite transmission with antibodies that attack sexual stage parasites in the mosquito vector (7,
59	8). Monoclonal antibodies to mosquito sexual stage (gamete) parasites were used to identify
60	candidate TBV antigens, including gamete surface proteins P230 and P48/45 first expressed by
61	gametocytes in human blood (9), and zygote surface proteins P25 and P28 expressed only post-
62	fertilization in the mosquito host (10, 11). These antigens are multi-domain cysteine-rich proteins
63	and generally difficult to produce as properly folded recombinant protein. P. falciparum P25
64	(Pfs25) antigen was the first expressed as recombinant protein (12) and has remained the leading
65	TBV candidate for three decades. In preclinical studies, Pfs25 vaccines have induced equal or
66	greater serum activity versus other candidate antigens or antigen combinations (13, 14).
67	While earlier P25 candidates failed to meet safety or activity criteria to advance in the clinic (15,
68	16), we recently reported that a Pfs25 protein-protein conjugate vaccine formulated in alum
69	adjuvant induced significant serum functional activity in both US (17) and Malian adults (18).
70	However, few vaccinees developed transmission reducing activity (TRA) >50% or significantly
71	increased their TRA after 2 or 3 doses of Pfs25 vaccine: 2/17 subjects after 2 doses and 2/15
72	after 3 doses in US adults (17); and no significant activity was seen in vaccinees (versus

It is made available under a CC-BY-NC-ND 4.0 International license .

73	comparators) after 3 doses in Malian adults (18). In each study, significant functional activity
74	required four vaccine doses, and antibody titers declined rapidly, suggesting functional
75	immunogenicity and durability must be improved before advancing TBV further in clinical
76	development. We hypothesized that the pre-fertilization protein Pfs230 alone or in combination
77	with Pfs25 would improve functional activity.
78	To assess the contribution of Pfs230 to a TBV, a fragment (Ser542 to Gly736) encompassing
79	domain 1 of Pfs230 cloned and expressed in P. pastoris (Pfs230D1, previously referred to as
80	Pfs230D1M) as described in (19) was chemically conjugated to EPA (20), a non-toxic mutant of
81	exoprotein A from P. aeruginosa using methods previously described for development of the
82	Pfs25-EPA vaccine (21). Here, we compare Pfs230D1-EPA to our benchmark TBV (Pfs25-EPA)
83	formulated in alum in three models (mice, nonhuman primates, and humans) and assess their
84	activity in combination.

It is made available under a CC-BY-NC-ND 4.0 International license .

86 **Results**

87	To confirm the benefit of conjugation of Pfs230D1, groups of CD-1 mice were immunized twice
88	(0, 28 days) by intramuscular injection with either Pfs230D1 or Pfs230D1-EPA, both formulated
89	in Alhydrogel [®] , which was the clinical formulation. Antibody titers induced by Pfs230D1-EPA
90	were ~100-fold greater than titers induced by Pfs230D1 monomer (Fig. S1). For clinical
91	development planning, we assessed Pfs230D1 and Pfs25 for their relative capacities to induce
92	functional antibodies, to determine if one antigen should be prioritized over the other for clinical
93	testing. Initial dose ranging studies with Pfs230D1-EPA were performed in mice in order to
94	determine appropriate doses to use for future mouse experiments (Fig. S2); subsequently all mice
95	were immunized with doses ranging from 0.1 to 3 μ g per immunization 28 days apart.
96	Data were collated from multiple experiments using both BALB/c and CD-1 outbred mice with
97	head-to-head comparisons of Pfs25-EPA/Alhydrogel ^{$@$} and Pfs230D1-EPA/Alhydrogel ^{$@$} for
98	functional antibody activity assessed by Standard Membrane Feeding Assay (SMFA) of P.
99	falciparum strain NF54 gametocytes to Anopheles stephensi mosquitoes (Fig. 1A). Parasite
100	Transmission-Reducing Activity (TRA, reduction in mean oocyst count per mosquito versus
101	control antibody) was plotted against ELISA titers for 4 separate experiments, containing 3
102	immunizing doses in each experiment. There was a titer-dependent positive correlation for both
103	antigens (Pfs230D1, r=0.68 P=0.02; Pfs25, r=0.58 P=0.06), with high TRA achieved at the
104	higher titers with both antigens, but with no difference between Pfs25 and Pfs230D1.
105	Multiple publications have shown a dependency on active complement for anti-Pfs230 inhibition
106	in preclinical studies (22-24). Therefore, serum samples from BALB/c mice immunized with
107	cGMP Pfs230D1-EPA/Alhydrogel [®] were tested by SMFA when mixed with intact or heat-
108	inactivated human sera. Again, sera from mice immunized with Pfs230D1-EPA inhibited oocyst

It is made available under a CC-BY-NC-ND 4.0 International license .

109	development in a dose-dependent manner and was not significantly different from that of Pfs25-
110	EPA sera (Fig. S3, Table S1). In the absence of active human complement in a dose titration
111	experiment, antibodies against both antigens blocked equally well.
112	Since mouse studies did not distinguish one antigen (Pfs25 or Pfs230D1) as superior over the
113	other for functional activity and therefore their prioritization for clinical testing, we hypothesized
114	a non-human primate model may reveal quantitative differences in activity of the two vaccine
115	candidates. We conducted a vaccine study in rhesus macaques using the clinical Alhydrogel®
116	formulation and doses of Pfs230D1-EPA (40 μ g Pfs230D1) and Pfs25-EPA (47 μ g Pfs25)
117	administered by intramuscular injection on a 0, 2, 6-month schedule, similar to a typical human
118	clinical trial regimen and schedule. Antibody titers were monitored to confirm Pfs25 and
119	Pfs230D1 immunogenicity (Fig. 1B, Fig. S4A, C). Sera from peak titers, collected two weeks
120	after the third dose (day 182), were used in SMFA to assess function in the presence of intact
121	human sera (Fig. 1B, Fig. S4B, D, and Table S2). Anti-Pfs25 immune sera demonstrated overall
122	modest inhibition of oocyst development, similar to previous preclinical and clinical experience.
123	In contrast, anti-Pfs230D1 had potent inhibitory activity, with all samples reducing oocyst
124	density by greater than 80%, and 3/6 achieving greater than 50% reduction in the prevalence of
125	infected mosquitoes, referred to as Transmission-Blocking Activity (TBA).
126	To measure the contribution of complement to the activity, serum samples from the Pfs230D1
127	group were tested again by SMFA, in the presence or absence of complement (Fig. 1C and
128	Table S3). Distinct from observations in mice, activity was significantly diminished in the
129	absence of complement (p=0.03, Wilcoxon Matched-Pairs signed rank test for difference
130	between groups). However, even without complement, 5/6 monkeys had greater than 50% TRA,

It is made available under a CC-BY-NC-ND 4.0 International license .

131	suggesting rhesus react to an epitope that blocks biological function. Thus, the rhesus model
132	indicated that Pfs230D1 was a superior vaccine target, in part due to the activity of complement.
133	After establishing that Pfs230D1-EPA/Alhydrogel® or Pfs25-EPA/Alhydrogel® were well-
134	tolerated, immunogenic, and induced functional activity in preclinical models, a phase 1 first-in-
135	human clinical trial was initiated to assess safety and to compare Pfs25-EPA/Alhydrogel®,
136	Pfs230D1-EPA/Alhydrogel [®] , or a combination of the two, before advancing either candidate to
137	field trials. US adults were vaccinated in a staggered manner for safety. Five subjects per arm
138	received two immunizations (0, 28 days) with Pfs230D1-EPA/Alhydrogel® or Pfs25-
139	EPA/Alhydrogel® or both co-administered in separate arms. Overall, vaccinations with all doses
140	of Pfs25-EPA/Alhydrogel [®] (16 μg; 47 μg), Pfs230D1-EPA/Alhydrogel [®] (5 μg; 15 μg; 40 μg),
141	and the combination (Pfs25 + Pfs230D1: 16 μ g + 15 μ g; 47 μ g + 40 μ g) were well-tolerated with
142	minimal local and systemic reactogenicity reported and no serious adverse events (Table S4).
143	Pfs25-EPA/Alhydrogel [®] elicited anti-Pfs25 antibodies at the high dose but not at the low dose
144	(Fig. 2B compared to 2A, p=0.03) while titers against Pfs230D1 were not dose-dependent (Fig.
145	2C, D, E). Combining low dose Pfs25-EPA/Alhydrogel [®] with low dose Pfs230D1-
146	EPA/Alhydrogel [®] elicited significantly higher anti-Pfs25 titers than low dose Pfs25-
147	EPA/Alhydrogel [®] alone (Fig. 2F compared to 2A, p=0.01); this effect was not observed with
148	high dose vaccine (Fig. 2G compared to 2B, p=0.12), and there was no potentiating effect of
149	vaccine combinations on anti-Pfs230 titers. Interestingly, anti-Pfs230 titers were measurable
150	even at the lowest Pfs230D1-EPA dose of 5 ug (Fig 2C), unlike the Pfs25-EPA vaccine (18),
151	suggestive of better intrinsic immunogenicity.
152	Sera from peak titers two weeks after the second dose in the high dose groups were measured for
153	functional activity (TRA and TBA) by SMFA. In general, TRA are used to compare results from

It is made available under a CC-BY-NC-ND 4.0 International license .

154	different studies owing to consistency between assays, while TBA varies between assays based
155	on parasite infectivity to mosquitoes (25). Consistent with previous published data (17) and with
156	preclinical studies, two doses of Pfs25-EPA did not induce titers sufficient to reduce
157	transmission (Fig. 3A and Table S5). However, aligning with the results seen in rhesus,
158	Pfs230D1 induced high functional activity in humans. TRA was >90% in 2/5 individuals from
159	the Pfs230D1-EPA arm (99%, 98%) and > 50% TRA in 2 others (73%, 62%), versus the Pfs25
160	group in which 0/5 individuals had TRA>50%, representing a significant improvement of
161	Pfs230D1-EPA over the benchmark Pfs25-EPA candidate (Fishers exact test, p<0.05). In the
162	Pfs25 + Pfs230D1 combination group, one individual had 90% and one had 65% TRA. TRA
163	correlated well with anti-Pfs230D1 titers (r=0.77, p=0.013) but not anti-Pfs25 titers (Fig 3B-C),
164	demonstrating that the functional activity is due to the Pfs230D1 vaccine. Titers achieved after 2
165	doses of Pfs25 vaccine were similar in two previous studies in malaria-naïve US individuals
166	(GM EU=147) (17) and malaria-exposed individuals in Mali (GM EU=93.1) (18) as in this study
167	(GM EU=160.1), when comparing individuals who received the same vaccine dosage.
168	Functional Pfs25 activity was also similar between the prior US study (17) and this study, with
169	few (2/17) or no (0/5) individuals with serum TRA>50%, respectively, after 2 vaccine doses;
170	serum TRA was not measured after vaccine dose 2 in the Mali field trial (18) and so cannot be
171	compared to the current study.
172	Again, as seen in the non-human primate model, dependency on complement was confirmed
173	with the Pf230D1 immune sera samples, as heat-inactivation of serum complement significantly
174	reduced (p=0.009, Wilcoxon matched-pairs signed rank test), but did not completely eliminate,
175	functional activity (Fig. 4A, B and Table S6). Sera from two individuals who received the
176	vaccine combination appeared to increase parasite transmission to mosquitoes after heat-

It is made available under a CC-BY-NC-ND 4.0 International license .

- inactivation (**Fig. 4D**); enhancement of *P. vivax* transmission has also been observed with
- naturally acquired antibodies or monoclonal antibodies used at low doses in membrane feeding
- assays (26). Naturally acquired serum transmission-enhancing activity has been observed against
- both *P. vivax* and *P. falciparum* (26-28), and this enhancing activity has been most apparent in
- 181 heat-inactivated sera (27). While this enhancing activity has not previously been associated to
- 182 Pfs230 antibodies in the absence of complement, our results echo these earlier findings.

183

It is made available under a CC-BY-NC-ND 4.0 International license .

185 **Discussion**

186	A transmission blocking vaccine could play a pivotal and unique role in malaria elimination
187	efforts, by inducing durable immune responses that interrupt human-to-mosquito malaria
188	transmission over an extended period of time. In our earlier clinical trials, the leading TBV
189	candidate Pfs25 induced functional activity at peak antibody titers, but the activity was lost
190	rapidly as titers decreased (17, 18). Here, we sought to increase TBV activity and durability by
191	combining the post-fertilization antigen Pfs25 with the pre-fertilization antigen Pfs230D1. We
192	found that Pfs230D1 was significantly more potent than Pfs25 as a vaccine, and the addition of
193	Pfs25 to Pfs230D1 did not appear to improve on this activity. The superior activity of Pfs230D1
194	over Pfs25 was predicted by preclinical studies in rhesus but not in mice and was largely
195	explained by complement-dependent activity seen with monkey and human but not rodent
196	antibody. Pfs230 or Pfs230 combination vaccines warrant further evaluation in field studies to
197	assess their potential as a tool for malaria elimination as do adjuvants that increase levels and
198	durability of functional antibody (29), particularly complement-fixing antibody isotypes.
199	TBV candidate antigens including Pfs230 have been challenging to prepare as properly folded
200	proteins, owing to their cysteine-rich sequence and highly folded structure. Importantly,
201	functional antibodies against these antigens commonly target conformation-dependent epitopes
202	(19). The Pfs230 extracellular fragment includes 14 domains with 6-cys structure, a motif that
203	has been particularly difficult to reproduce as recombinant antigen. Earlier studies showed that a
204	Pfs230 polypeptide (Pfs230-C, amino acids 443-1132) encompassing an upstream region,
205	domain 1 through 3, and 9 amino acids in domain 4 (30) or a polypeptide (Pfs230D1-2)
206	encompassing an upstream region, domain 1 through 2 (19), induces functional antibodies in
207	animal studies Here, we used Pichia expression system to generate properly folded Pfs230

It is made available under a CC-BY-NC-ND 4.0 International license .

208	domain 1 which induced more potent antibodies in rabbits compared to the Pfs230D1-D2
209	polypeptide in the ex vivo SMFA (19), after prior success expressing full-length extracellular
210	Pfs25 in <i>Pichia</i> (31) that induced functional antibodies in human studies (17). Our preclinical
211	studies consistently demonstrated Pichia-expressed Pfs230D1 reacted to conformation-
212	dependent functional monoclonal antibodies (19) and induced functional IgG in immunized
213	animals.
214	Recent studies in mice suggested that Pfs25 immunogens were similar (13) or superior (14) to
215	Pfs230 immunogens for inducing functional antibodies that block parasite transmission. In mice,
216	we similarly found no significant differences in the ability of Pfs25 and Pfs230D1 recombinant
217	immunogens prepared as conjugate nanoparticle vaccines to induce antibody activity in mice.
218	However, our studies in monkeys suggested that the Pfs230D1 immunogen was significantly
219	more potent for inducing serum functional activity. The difference between models can be
220	explained at least partly by the complement-dependent nature of Pfs230-induced activity, which
221	was pronounced in assays with monkey but not mouse antibody. Early studies using mouse
222	monoclonal antibodies raised against native Pfs230 on gametes revealed functional antibodies
223	restricted to IgG2a and IgG2b subclasses, with complement-mediated lysis being the putative
224	mechanism of transmission blockage (22-24) with the exception of the murine mAb 4F12,
225	isotype IgG1 which has been crystallized in complex with Pfs230D1 (32) and effectively blocks
226	transmission independent of complement (19).
227	We examined antibody subclasses and isotypes to assess the role of complement-fixing antibody.
228	In a previous study, we showed that mice immunized with Pfs230D1 showed a dominant IgG1
229	isotype response (33) which is non-complement-fixing in mice. In the present study, we
230	measured Pfs230D1-specific antibody isotypes in sera from rhesus macaques that received either

It is made available under a CC-BY-NC-ND 4.0 International license .

231	$Pfs230D1-EPA/Alhydrogel \ensuremath{\mathbb{R}}\ alone \ or \ Pfs25-EPA/Alhydrogel \ensuremath{\mathbb{R}}\ + \ Pfs230D1-EPA/Alhydrogel \ensuremath{\mathbb{R}}\ black alone \ or \ Pfs25-EPA/Alhydrogel \ensuremath{\mathbb{R}}\ black \ensuremath{\mathbb{R}$
232	combination, two weeks after the second and third vaccinations (Fig. S5); and from human
233	vaccinees 2 weeks after the second vaccination (Fig. S6). In both rhesus and humans, we
234	observed that IgG1, which has the highest complement-fixing ability, was the dominant isotype
235	induced, while the non-complement fixing IgG2 and IgG4 were significantly lower. Two human
236	vaccinees produced appreciable amounts of IgG3 which is also complement-fixing. Pfs230-
237	specific IgM, which also have complement-fixing properties, was readily detected in 4 of the 5
238	vaccinees but they were consistently lower than the IgG1 isotype in all samples. We surveyed
239	Day 84 sera for five subjects that had TRA on Day 56, and significant functional activity
240	persisted for 4/5 subjects (Fig. S7A). We compared IgG and IgM purified from Day 84 sera of
241	two subjects (Subjects #7 and #10) in SMFA, and oocyst counts were significantly lower in the
242	presence of IgG than IgM (for Subject #7, $p = 0.042$; for Subject #10, $p = 0.006$; for both
243	subjects combined, $p = 0.001$, Fig. S7B). Both serum and IgG from Subject #7 were tested for
244	membrane attack complex (MAC) formation on gametes, showing MAC formation in assays
245	using intact but not heat-inactivated sera (Fig. S7C, D, E, F). These results are consistent with
246	recent evidence that human monoclonal antibodies we generated from Pfs230D1 vaccinees also
247	induce MAC formation on gametes in the presence of intact but not heat-inactivated sera (34).
248	Of note, mouse polyclonal sera induced by vaccination with an alum-based adjuvant conferred
249	activity in the absence of the complement pathway. Additionally, rhesus immune sera
250	significantly reduced transmission in the absence of complement, demonstrating other
251	complement-independent mechanisms, such as neutralization. Indeed, in the clinical trial,
252	function in one subject was not completely ablated in the absence of complement (Fig. 4B). We

It is made available under a CC-BY-NC-ND 4.0 International license .

are currently exploring mechanisms by which rodent mAb 4F12 might neutralize gametes in the
 absence of complement activity.

255	Our initial goal for the human studies was to examine whether a combination of Pfs25 with the
256	pre-fertilization antigen Pfs230D1 was safe and might induce more potent and longer-lived
257	activity than Pfs25 alone. In previous rodent studies, a combination of yeast-expressed Pfs25 and
258	Pfs28 induced greater activity than either antigen alone (35), but combinations of Pfs25 and
259	Pfs28 or of Pfs25 and Pfs230-C delivered as virus-vectored vaccines did not yield additional
260	activity (14). Ultimately, each antigen combination must be tested empirically for positive or
261	negative interference in humans. Here, we observed that Pfs230D1 alone formulated in
262	Alhydrogel® (which has relatively modest immunopotentiating activity) could induce functional
263	serum activity after only two doses in some individuals, suggesting vaccine activity could be
264	enhanced by increasing the number of doses or by alternative adjuvants. Further, the addition of
265	Pfs25 to Pfs230D1 during immunization did not provide additional activity. We are currently
266	evaluating alternative adjuvants for their ability to enhance TBV activity, by increasing antibody
267	titers and durability particularly for complement-fixing IgG subclasses.
268	Taken together, the data show two conclusions: 1) Pfs230D1 is a superior transmission-blocking
2 ()	

antigen to Pfs25, and 2) the rhesus model is more predictive of the functional human immune

response to Pfs230D1 than is the mouse model. The results from these studies yield valuable

information for future studies to understand immune responses to Pfs230D1 and how

improvements in vaccine development may lead to a licensed TBV.

It is made available under a CC-BY-NC-ND 4.0 International license .

274 Methods

275 <u>Animal Studies</u>

276	Five to 8-week-old naïve, female BALB/c or CD-1 mice were purchased from Taconic
277	Laboratories (Hudson, NY) and maintained at a facility at the NIH. Immunizations were
278	performed by either intraperitoneal or intramuscular (i.m.) injection in the anterior tibialis in a
279	volume of 50 μ L using a standard day 0 and day 28 regimen. <i>Macaca mulatta</i> (rhesus) were
280	randomized by age, sex, and weight, and were maintained in an AAALAC accredited NIAID
281	facility. Vaccinations were performed on days 0, 56, and 168 by intramuscular injection in a
282	volume of 0.6 mL (Pfs25-EPA/Alhydrogel) or 0.8 mL Pfs230D1-EPA/Alhydrogel) in the leg,
283	alternating legs for boosting injections.
284	
285	Clinical Study Procedures
286	The clinical study was designed as an open label, dose escalation study to examine the safety and
287	immunogenicity of Pfs230D1-EPA/Alhydrogel [®] and Pfs25M-EPA/Alhydrogel [®] alone or co-
288	administered. The initial open-label dose-escalating, two-dose regimen (0, 1 month; n=5/group)
289	was performed in the US prior to a larger double-blinded study conducted in Mali. Participants
290	were sequentially enrolled in the following manner. No blinding or placebo arms were
291	implemented. No randomization occurred.
292	
293	ELISA
294	Immulon 4 HBX flat bottom microtiter plates (Dynex Technologies) ELISA plates were coated
295	with 1 μ g/ml of antigen in a volume of 100 μ L per well in carbonate coating buffer (pH 9.6)
296	overnight at 4°C. After blocking in 5% skim milk in TBS blocking buffer in a volume of 320 μ L
297	per well for 2 hrs, samples were serially diluted in TBS/5% milk and plated in triplicate in a

It is made available under a CC-BY-NC-ND 4.0 International license .

298	volume of 100 μ L per_well and incubated at room temperature for 2 hours. Plates were washed 4		
299	times and alkaline phosphatase labeled goat anti-mouse IgG (H+L), goat anti-human IgG (H+L),		
300	or goat anti-monkey phosphatase labeled secondary antibody (Seracare Life Sciences) was added		
301	in a volume of 100 μ L per well and incubated at room temperature for 2 hours. After washing 4		
302	times, dissolved phosphatase substrate tablets (Sigma) were added in a volume of 100 μ L per		
303	well and plates were incubated for 20 minutes before optical densities (OD) were measured with		
304	a Spectramax 340PC (Molecular Devices). Each ELISA plate contained an internal serum		
305	standard from which a four-parameter curve was calculated with Softmax software. According to		
306	laboratory SOP, any samples for which ELISA results from triplicate wells exceeded a pre-		
307	specified CV were repeated. ELISA Units were assigned to test samples based on the sera		
308	dilution that gave an OD of 1.0, adjusted to the internal standard. For the Pfs230 isotyping		
309	assays, similar procedures were followed and the list of detecting antibodies utilized are listed in		
310	Supplementary table S7.		
311			
312	Transmission Blocking and Reducing Activity		
313	Transmission blocking activity (TBA, reduction in infection prevalence) and transmission		
314	reducing activity (TRA, reduction in infection intensity) of the sera were tested by an ex vivo		
315	standard membrane feeding assay (SMFA) as described previously (13). Briefly, an in vitro 14-		
316	16 day old gametocyte culture of <i>P. falciparum</i> (NF54 line) was evaluated for stage V		
317	gametocytes (>0.5%) and the presence of exflagellation centers observed at 400X magnification		
318	(>1 per field). The culture was diluted with washed O+ red blood cells (RBCs) from a malaria		
319	naïve donor (Interstate Blood Bank, Memphis, Tennessee) to achieve $0.12\% \pm 0.05\%$		
320	concentration of Stage V gametocytes. For each sample, 100 μ L of the pelleted diluted culture		

It is made available under a CC-BY-NC-ND 4.0 International license .

(100% hematocrit) was mixed with 160 µL of test serum. For human sera samples, 160 µL was 321 used neat; for rhesus sera samples, 60 µL of test sera was mixed with 100 µL of a pool of naïve 322 human AB⁺ sera; for mouse sera samples, 20 or 30 μ L of test sera was mixed with 130 μ L of 323 pooled naïve sera. All samples were immediately fed to pre-starved (~24 hours) 3-8 day old 324 Anopheles stephensi (Nijmegen strain) mosquitoes through a Parafilm[®] membrane stretched 325 across a glass mosquito feeder kept warm by a circulating water membrane at 40°C. Test sera 326 were not heat-inactivated. Post feeding, mosquitoes were maintained for 8 days at 27°C and 80% 327 328 humidity conditions to allow for the development of parasites. Infectivity was measured by dissecting at least 20 gravid mosquitoes per sample, staining the midguts with 0.05% 329 mercurochrome solution in water for 20 minutes and counting the number of oocysts on each 330 midgut. The feeding experiment was not analyzed unless the average oocyst count in the assay 331 control mosquitoes (at least 20 dissected mosquitoes fed with naïve heat-inactivated serum) was 332 more than four. The TBA and TRA are calculated by the following formulas: 333

334
$$TRA = 100 \times \left(\frac{Mean \ Oocyst \ Number_{neg \ ctrl} - Mean \ Oocyst \ Number_{test}}{Mean \ Oocyst \ Number_{neg \ ctrl}}\right)$$

335

and

$$TBA = 100 \text{ x} \left(\frac{Mean No. Inf. Mosquito_{neg ctrl} - Mean No. Inf. Mosquito_{test}}{Mean No. Inf. Mosquito_{neg ctrl}} \right)$$

341

342 Immunofluorescence assay to assess the deposition of the membrane attack complex (MAC)

343	Formation of membrane attack complex (MAC) and further activation of the complement system
344	were assessed using Immunofluorescence of live female gamete parasites. Briefly, 5 mL of a
345	Plasmodium falciparum NF4 gametocyte stage V culture were centrifuged at 2,000 rpm for 5
346	minutes and added to an exflagellation medium containing 900 μ L of RPMI, 100 μ L of PBS and
347	1 μ L of xanthurenic acid, then left for 1.5 hours at room temperature. Cells were resuspended in
348	5 mL of RPMI and applied to a 15 mL Nycodenz gradient (16%, 11% and 6%), then centrifuged
349	at 7,000 x g for 30 minutes. Parasites located in the interface between 6% and 11% were
350	collected into 50 mL of RPMI and spun down at 2,000 x g for 10 minutes. Parasites were then
351	incubated with serum or 100 μ g/mL of total IgG previously purified from subject 30G and
352	diluted in PBS. IgG1 isotype control with heavy and kappa chains was purchased from Creative
353	Biolabs. The suspension was incubated at 37° C for 45 minutes with either 50 μ L of intact sera or
354	sera heat-inactivated at 56°C, both obtained from US healthy donor. Subject serum was used
355	directly without supplementation. During the incubation the tubes were gently mixed every 10
356	minutes to facilitate C5b-9 and C5b-8 deposition on cells. Two mL of cold PBS were used to
357	stop the reaction and to wash the cells. Suspension was centrifuged at 500 x g for 5 minutes and
358	the pellet was then incubated with 10ug/mL of the mAb anti-C5b-9 + C5b-8 (Abcam, ref
359	ab66768) for 2 hours on ice. Cells were washed with PBS, centrifuged at 500 x g for 5 minutes
360	and stained with Hoechst 33342 Solution (Thermo Fisher) diluted at 1:20,000 for 8 minutes and
361	further washed with PBS. Cells were kept in parasite culture media until the imaging was
362	performed in a TCS SP8 MP microscope (Leica, Wetzlar, Germany) at 37°C. Quantification
363	analyses was performed assessing the mean fluorescence per nuclei stained.
2.64	

364

365 <u>Statistics</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

366	All statistical tests were performed using Prism v7.0 by GraphPad Software, Inc. Pearson's
367	correlation coefficient for the pairs of log-titer and TRA stratified by titer type were conducted
368	for Figure 1A. Figure 2, Day 42 values of panel A vs F, B vs G, and A vs B were conducted by
369	separate Wilcoxon rank sum tests with continuity correction. Figure 2 panels C vs D vs E were
370	compared with a Kruskal-Wallis rank sum test. Figure 3A showcases 15 Kruskal Wallis tests
371	(each animal compared with the naïve-pool as a control) with a Dunn-Bonferroni adjustment.
372	Spearman's coefficient and exact p-values were calculated for both Figure 3B and Figure 3C.
373	Figures 4A-D showcase Wilcoxon matched pairs signed-rank tests; each panel had 5 pairwise
374	tests performed. Asterisks indicate $p < 0.05/5 = 0.01$. Figure S1 reports exact p-values for each
375	of 3 Mann-Whitney tests. Figure S3 (and Table S1) displays 6 Kruskal Wallis tests performed
376	for intact sera where each comparison involves the control and the p-values are Dunn-Bonferroni
377	corrected. The same procedure was repeated for the Hi-Sera group with a different control in
378	Figure S3. Figure S4 (and Table S2) display the results for 12 pre-vac vs post-vac Wilcoxon
379	matched-pairs signed rank tests. Table S3 contains the results of 6 intact vs heat-inactivated
380	Wilcoxon matched-pairs signed rank tests.
381	
382	Study Approval
383	Animal Studies. All animal procedures were performed according to protocols approved by the
384	NIAID and NIH Animal Care and Use Committee. All procedures were in accordance with the
385	Guide for the Care and Use of Laboratory Animal Reports NIH 85-23.
386	
387	Human Ethics Statement. This open label phase 1 trial was performed at the National Institutes
388	of Health (NIH) Clinical Trial Center in Bethesda, MD. The study was conducted under an

It is made available under a CC-BY-NC-ND 4.0 International license .

- investigational new drug application (IND) with the US Food and Drug Administration
- 390 (#16251). The protocol was approved by the Institutional Review Board (IRB) of the National
- 391 Institute of Allergy and Infectious Diseases (NIAID) and under trial investigation number at
- 392 ClinicalTrials.gov (NCT02334462). All participants gave written informed consent in order to
- 393 participate in the study.

It is made available under a CC-BY-NC-ND 4.0 International license .

Author contributions

- 396 SAH, CA, EEG, KMR, YW, PED designed and conceptualized the study. KMR, DZ, RH, PVS,
- 397 NJM, LEL, CHC, JPR, YW, DLN conducted the experiments. SAH, CA, AM, HD, CVH, OM,
- 398 IZ conducted clinical investigation. CA, BJS, IZ analyzed the results. CA, BJS, EEG curated the
- data. SAH and CA visualized data and wrote the manuscript; all authors reviewed and edited the
- 400 manuscript. SAH and PED supervised the study, and PED supervised all teams.

It is made available under a CC-BY-NC-ND 4.0 International license .

401 Acknowledgments

We are grateful to the following at LMIV: the Clinical Trials Team which includes Regina 402 403 White, Alemush Imeru, and Kattie Khadar; the Data Manager Rathy Mohan; the Project Manager Sharon Wong-Madden. We thank Vu Nguyen, Richard Shimp, Jr., and Karine Reiter 404 for oversight of the production and release of bulk conjugated vaccine. We also thank Holly 405 McClellan and Weili Dai for their assistance in vaccine quality control evaluation. We are 406 grateful for the work by Emily Kelnhofer and Ashley McCormack on the SMFA results; by Joan 407 Aebig, Andrew Orcutt, and Sarah Brockley for ELISA data; by Nada Alani for isotyping 408 ELISAs; and by Matthew Cowles for antibody purification. Thank you to NIH Clinical Center 409 Outpatient Clinic 8 staff, in particular Karen Evans and Pam Stoll, and to NIH Clinical Center 410 411 Pharmacy staff. Also, our appreciation to the extensive work completed by the LMIV animal team including Sachy Orr-Gonzalez, Brandi Butler, and Tarik Ouahes. In addition, we thank J. 412 Patrick Gorres for assisting with writing, editing, and visualization. 413 414 We thank the CRIMSON team at NIAID for providing assistance in the development and 415

finalization of the case report forms and database. We thank OCRPRO for providing external
 monitoring services for this study and ongoing support and guidance to our NIAID programs,
 specifically Erin Rudzinski, Lisa Giebeig, Shelly Simpson, and Susan Vogel.

- 419
- 420

It is made available under a CC-BY-NC-ND 4.0 International license .

421 **References**

- Bjorkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, et al. From high to low malaria transmission in Zanzibar-challenges and opportunities to achieve elimination.
 BMC Med. 2019;17(1):14.
- 2. Cook J, Hergott D, Phiri W, Rivas MR, Bradley J, Segura L, et al. Trends in parasite
 prevalence following 13 years of malaria interventions on Bioko island, Equatorial
 Guinea: 2004-2016. *Malar J*. 2018;17(1):62.
- 428 3. WHO. Geneva, Switzerland: World Health Organiation; 2019.
- 4. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, et al.
 Economic analysis of the global polio eradication initiative. *Vaccine*. 2010;29(2):334-43.
- 431 5. Fenner F. Risks and benefits of vaccinia vaccine use in the worldwide smallpox
 432 eradication campaign. *Res Virol.* 1989;140(5):465-6; discussion 87-91.
- 433
 434
 434
 435
 6. Riviere M, Tretiak R, Levinton C, Fitzsimon C, and Leclerc C. Economic benefits of a routine second dose of combined measles, mumps and rubella vaccine in Canada. *Can J Infect Dis.* 1997;8(5):257-64.
- 436
 437
 7. Carter R, and Chen DH. Malaria transmission blocked by immunisation with gametes of the malaria parasite. *Nature*. 1976;263(5572):57-60.
- 4388.Gwadz RW. Successful immunization against the sexual stages of Plasmodium439gallinaceum. Science. 1976;193(4258):1150-1.
- 440
 441
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 441
 442
 442
- 44310.Duffy PE, Pimenta P, and Kaslow DC. Pgs28 belongs to a family of epidermal growth444factor-like antigens that are targets of malaria transmission-blocking antibodies. J Exp445Med. 1993;177(2):505-10.
- 446 11. Grotendorst CA, Kumar N, Carter R, and Kaushal DC. A surface protein expressed
 447 during the transformation of zygotes of Plasmodium gallinaceum is a target of
 448 transmission-blocking antibodies. *Infect Immun.* 1984;45(3):775-7.
- Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, and Kaslow DC. Recombinant
 Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity
 in experimental animals. *J Exp Med.* 1991;174(5):1203-8.
- 452 13. Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, et al. Comparative
 453 assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
 454 Sci Rep. 2015;5:11193.
- 455 14. Menon V, Kapulu MC, Taylor I, Jewell K, Li Y, Hill F, et al. Assessment of Antibodies
 456 Induced by Multivalent Transmission-Blocking Malaria Vaccines. *Front Immunol.*457 2017;8:1998.
- Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, et al. Phase 1
 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. *Vaccine*. 2005;23(24):3131-8.
- 461
 461
 462
 462
 463
 463
 464
 465
 465
 465
 466
 466
 466
 467
 468
 468
 469
 469
 469
 460
 460
 460
 460
 460
 461
 461
 462
 462
 463
 463
 463
 464
 465
 465
 465
 466
 466
 467
 467
 468
 468
 469
 469
 469
 460
 460
 460
 460
 461
 461
 462
 462
 463
 463
 464
 465
 465
 465
 466
 467
 467
 468
 468
 469
 469
 469
 469
 469
 469
 460
 460
 460
 460
 461
 461
 462
 462
 463
 464
 465
 465
 465
 466
 467
 467
 468
 468
 468
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
- Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, et al. Safety and
 Immunogenicity of Pfs25-EPA/Alhydrogel(R), a Transmission Blocking Vaccine against

It is made available under a CC-BY-NC-ND 4.0 International license .

466		Plasmodium falciparum: An Open Label Study in Malaria Naive Adults. PLoS One.
467		2016;11(10):e0163144.
468	18.	Sagara I, Healy SA, Assadou MH, Gabriel EE, Kone M, Sissoko K, et al. Safety and
469		immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against
470		Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-
471		escalation study in healthy Malian adults. <i>Lancet Infect Dis.</i> 2018;18(9):969-82.
472	19.	MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, et al. Structural
473		and Immunological Characterization of Recombinant 6-Cysteine Domains of the
474		Plasmodium falciparum Sexual Stage Protein Pfs230. J Biol Chem. 2016;291(38):19913-
475		22.
476	20.	Burkhardt M, Reiter K, Nguyen V, Suzuki M, Herrera R, Duffy PE, et al. Assessment of
477		the impact of manufacturing changes on the physicochemical properties of the
478		recombinant vaccine carrier ExoProtein A. Vaccine. 2018.
479	21.	Shimp RL, Jr., Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, et al. Development of a
480		Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated
481		nanoparticle. Vaccine. 2013;31(28):2954-62.
482	22.	Quakyi IA, Carter R, Rener J, Kumar N, Good MF, and Miller LH. The 230-kDa gamete
483		surface protein of Plasmodium falciparum is also a target for transmission-blocking
484		antibodies. J Immunol. 1987;139(12):4213-7.
485	23.	Read D, Lensen AH, Begarnie S, Haley S, Raza A, and Carter R. Transmission-blocking
486		antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum
487		gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol.
488		1994;16(10):511-9.
489	24.	Roeffen W, Geeraedts F, Eling W, Beckers P, Wizel B, Kumar N, et al. Transmission
490		blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype
491		dependent. Infect Immun. 1995;63(2):467-71.
492	25.	Miura K, Swihart BJ, Deng B, Zhou L, Pham TP, Diouf A, et al. Transmission-blocking
493		activity is determined by transmission-reducing activity and number of control oocysts in
494		Plasmodium falciparum standard membrane-feeding assay. Vaccine. 2016;34(35):4145-
495		51.
496	26.	Healer J, McGuinness D, Carter R, and Riley E. Transmission-blocking immunity to
497		Plasmodium falciparum in malaria-immune individuals is associated with antibodies to
498		the gamete surface protein Pfs230. Parasitology. 1999;119 (Pt 5):425-33.
499	27.	Mendis KN, Munesinghe YD, de Silva YN, Keragalla I, and Carter R. Malaria
500		transmission-blocking immunity induced by natural infections of Plasmodium vivax in
501		humans. Infect Immun. 1987;55(2):369-72.
502	28.	Stone W, Bousema T, Sauerwein R, and Drakeley C. Two-Faced Immunity? The
503		Evidence for Antibody Enhancement of Malaria Transmission. Trends Parasitol.
504		2019;35(2):140-53.
505	29.	Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, et al. Adjuvant
506		and carrier protein-dependent T-cell priming promotes a robust antibody response against
507		the Plasmodium falciparum Pfs25 vaccine candidate. Sci Rep. 2017;7:40312.
508	30.	Williamson KC, Keister DB, Muratova O, and Kaslow DC. Recombinant Pfs230, a
509		Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity
510		of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol. 1995;75(1):33-42.

- 511 31. Tsai CW, Duggan PF, Shimp RL, Jr., Miller LH, and Narum DL. Overproduction of
 512 Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression,
 513 folding and O-linked glycosylation of a malaria vaccine candidate expressed in P.
 514 pastoris. *J Biotechnol.* 2006;121(4):458-70.
- Singh K, Burkhardt M, Nakuchima S, Herrera R, Muratova O, Gittis AG, et al. Structure
 and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230Pfs48/45 proteins. *Commun Biol.* 2020;3(1):395.
- Scaria PV, Rowe CG, Chen BB, Muratova OV, Fischer ER, Barnafo EK, et al. Outer
 membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230.
 NPJ Vaccines. 2019;4:24.
- 52134.Coelho CH, Tang WK, Burkhardt M, Galson JD, Muratova O, Salinas ND, et al. A high522affinity human monoclonal antibody against Pfs230 binds multiple parasite stages and523blocks oocyst formation in mosquitoes. 2020:2020.09.25.313478.
- 52435.Duffy PE, and Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically525linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect526Immun. 1997;65(3):1109-13.

528

527

Figures

5

10

Fig. 1. While (A) mouse studies comparing Pfs25-EPA/Alhydrogel® versus Pfs230D1-EPA/Alhydrogel® revealed no difference in immunogenicity or functional activity, (B) rhesus studies suggest Pfs230D1 is superior to Pfs25 and (C) requires active complement. (A) Mouse sera samples collected after immunization with Pfs25-EPA/Alhydrogel® or Pfs230D1-EPA/Alhydrogel® were used in SMFA to measure antibody function. Each data point represents a pool of sera from one immunization group (n=10/grp). The titer shown in the x-axis is the titer in the mosquito feeder after dilution. (B) Rhesus monkey sera samples collected two weeks after the third immunization with Pfs25-EPA/Alhydrogel® or Pfs230D1-EPA/Alhydrogel® were used in SMFA to measure antibody function. Each data point represents an individual animal. The titer shown on the x-axis is the tier in the mosquito feeder after dilution. %TRA is relative to pre-bleed samples from each animal; (C) Sera from the Pfs230D1-EPA/Alhydrogel® group were divided in two for heat inactivation followed by SMFA.



Fig. 2. Antibody titers by ELISA in humans. Antibody titers from each vaccine arm. Vaccinations were performed on days 0 and 28 at escalating doses (n=5/arm).



Fig. 3. Anti-Pfs230D1 has functional activity after 2 doses in humans. Vaccination induces functional antibodies after 2 doses. Sera from subjects (n=5/grp) were collected 2 weeks after 2nd dose and used for SMFA. Each data point represents the oocyst count from one mosquito. n.p., naïve sera pool. * p<0.05 difference from naïve pool, 15 pairwise Kruskal-Wallis tests with Bonferroni correction for multiple comparisons. Figure data are also represented in Table S5.



Fig. 4. Functional activity of anti-Pfs230 requires active complement in humans. Pfs230D1 requires complement for activity. Sera from subjects vaccinated with Pfs230D1-EPA/Alhydrogel or Pfs230D1-EPA+Pfs25-EPA/Alhydrogel were divided in two for complement inactivation and used for SMFA. Each data point represents the oocyst count from one mosquito. *p<0.05 difference between post-vaccine and pre-bleed sera from individuals, Wilcoxon matched pairs signed-rank test with Bonferroni adjustment. Figure data are also represented in Table S6.





Supplementary Materials

Human Study Objectives and Design

Figures S1-S7

Tables S1-S7